Rapport Therapeutics prices $380 million capital raise

Rapport Therapeutics Inc. (RAPP) raised $380M via a public offering of $175M in common stock at $21/share, $25M in pre-funded warrants, and $150M in convertible notes. The company also secured a $30M private placement. Proceeds will fund clinical trials and R&D. The offerings are expected to close by October 30, 2026.

Original reporting
Published Oct 28, 2026, 10:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 28, 2026, 10:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$RAPP
Bearish
high confidence
Mentioned
$RAPP
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RAPPBearishMed
01

Why it matters

The capital raise secures runway to 2029, but immediate share dilution may depress the stock.

02

Market read

First disclosure of a large financing package for a mid‑cap biotech; likely short‑term price impact.

03

What to watch

Potential strategic partnerships or future licensing deals tied to the raised capital are not disclosed.

Relevance 9/10Novelty 9/10Timing: today

Background

Rapport Therapeutics is a clinical‑stage biotech developing RAP‑219 for rare diseases.

Company-level read

Ticker impact

$RAPPBearishHigh confidence
Context

Rapport Therapeutics announced pricing of a $380 million capital raise including a $175 million stock offering, $150 million convertible notes and a $30 million private placement.

Expected impact

likely downward pressure as dilution outweighs cash infusion

Evidence & confidence

First‑report of a multi‑hundred‑million raise; market typically reacts negatively to dilution despite long‑term cash runway.

Market effects

Provides biotech sector with a sizable new financing example, may set precedent for other clinical‑stage firms seeking capital.

US biotech financing activity modestly boosted overall capital‑raising sentiment.

Limited to investors tracking biotech funding; no broader macro effect.

Counterpoint

The cash infusion could fund pivotal trials that unlock significant upside, offsetting dilution concerns.

Key entities

  • Morgan Stanley

    Joint book‑running manager for the offerings.

  • Leerink Partners

    Joint book‑running manager for the offerings.

  • Evercore ISI

    Joint book‑running manager for the offerings.

Related articles

$RAPPMed

Rapport Therapeutics 3Q 2026: Revenue $0 Net loss $40.2M, EPS $(0.84) — 10-Q Summary

Rapport Therapeutics reported no revenue and a net loss of $40.2M in 3Q 2026, widening from a $26.9M loss in the prior-year quarter. Diluted EPS was $(0.84). The company began Phase 3 trials for RAP-219 in epilepsy and plans further trials in 2027. Collaboration revenue from Tenacia was $20M for the nine months. According to the company, they deferred one program and prioritized another.

$RAPPHighAI 9/10

Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update

Rapport Therapeutics, Inc. (RAPP) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update Positive topline results from Phase 2 trial of RAP-219 in bipolar mania; initiation of two Phase 3 trials in bipolar mania expected in 2H 2027 Data from the Phase 2 FOS open-label

$RAPPMedAI 9/10

Rapport Announces Closing of Public Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Notes, as well as Concurrent Private Placement

Rapport Therapeutics (RAPP) closed public offerings of 9.76M shares of common stock at $21.00 per share, $172.5M in convertible notes, and a concurrent private placement of 1.43M shares. Total net proceeds are approximately $410.7M. Proceeds will fund clinical trials, R&D, and general corporate purposes. The notes have a 2.25% interest rate and mature in 2032.